Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Net Income (2018 - 2025)

Historic Net Income for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.

  • Exagen's Net Income fell 4095.07% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 1269.68%. This contributed to the annual value of -$15.1 million for FY2024, which is 3619.4% up from last year.
  • According to the latest figures from Q3 2025, Exagen's Net Income is -$7.1 million, which was down 4095.07% from -$4.4 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Net Income ranged from a high of -$3.0 million in Q2 2024 and a low of -$15.1 million during Q4 2022
  • In the last 5 years, Exagen's Net Income had a median value of -$6.2 million in 2021 and averaged -$6.8 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 12886.12% in 2022, then surged by 6582.82% in 2023.
  • Exagen's Net Income (Quarter) stood at -$7.1 million in 2021, then tumbled by 114.33% to -$15.1 million in 2022, then soared by 63.35% to -$5.5 million in 2023, then surged by 32.11% to -$3.8 million in 2024, then plummeted by 88.43% to -$7.1 million in 2025.
  • Its Net Income was -$7.1 million in Q3 2025, compared to -$4.4 million in Q2 2025 and -$3.8 million in Q1 2025.